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ABSTRACT: Flucloxacillin is a β-lactam antibiotic associated with
a high incidence of drug-induced liver reactions. Although
expression of HLA-B*57:01 increases susceptibility, little is
known about the pathological mechanisms involved in the
induction of the clinical phenotype. Irreversible protein mod-
ification is suspected to drive the reaction through the presentation
of flucloxacillin-modified peptides by the risk allele. In this study,
the binding of flucloxacillin to proteins of liver-like cells was
characterized. Flucloxacillin was shown to bind to proteins
localized in bile canaliculi regions, coinciding with the site of
clinical disease. The localization of flucloxacillin was mediated
primarily by the membrane transporter multidrug resistance-
associated protein 2. Modification of multiple proteins by
flucloxacillin in bile canaliculi regions may provide a potential local source of neo-antigens for HLA presentation in the liver.
Flucloxacillin is a β-lactam antibiotic associated with a highincidence of drug-induced cholestatic liver injury.
Although the pathological mechanisms involved in the
induction of the clinical phenotype remain to be defined,
both non-immune- and immune-mediated mechanisms may be
involved. A non-immune-mediated mechanism that involves
activation of HSP27 and the sequential molecular events was
reported for flucloxacillin-induced cholestasis.1,2 On the other
hand, the strong association of HLA-B*57:01 with fluclox-
acillin-induced liver injury3 and the detection of flucloxacillin-
specific T-cells in patient liver4 and flucloxacillin-specific CD8+
T-cells from peripheral blood mononuclear cells5 suggest that
the adaptive immune system is directly involved in the tissue
pathology.
Flucloxacillin has previously been shown to bind covalently
to nucleophilic lysine residues on proteins such as human
serum albumin, and such adducts were found in the sera of
patients receiving the antibiotic.6 For such reactive drugs,
covalent binding to intracellular proteins, peptide-HLA
complexes, and the HLA molecule itself is all possible. We
have recently shown that flucloxacillin forms protein adducts in
immune-like cells (C1R B lymphoblastoid), and flucloxacillin
haptenated peptides can be presented by HLA-B*57:01.7
However, whether flucloxacillin can form hepatic antigens that
activate local immune cells remains to be seen. Previously,
Burban et al. have shown that flucloxacillin induced direct
cholestatic effects in hepatocytes through activation of the
JAK/ROCK signaling pathway.2 However, the events leading
up to activation of the pathway are largely unknown and yet to
be defined. We hypothesized that transport-dependent cellular
accumulation of flucloxacillin can either induce cellular stress
or covalent binding to proteins, leading to activation of the
JAK/ROCK signaling pathway. This study was therefore
performed to investigate the effect of cell membrane
transporters on the transportation of flucloxacillin and covalent
binding of flucloxacillin to proteins using the liver cell lines
HepG2 and HepaRG.
We first assessed the flucloxacillin cholestatic risk using
HepaRG cells, which were cultured in growth media for 1.5
weeks, and then differentiated in 50:50 growth/differentiation
media for 0.5 weeks and differentiation media for a further 4
weeks (Figure S1). Following differentiation, cells were treated
with flucloxacillin (0.1 μM−10 mM) and the bile acid mixture
(1%, v/v) for 24 h. The cholestatic risk of a compound is
determined by calculating the cholestatic index (CIx), CIx =
(EC50 − ATP compound and bile acids)/(EC50 − ATP
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compound alone). Cholestatic risk is recorded when CIx ≤
0.80.8 Based on the CIx value, flucloxacillin was classified as a
compound that had cholestatic risk (CIx = 0.56 ± 0.11). A
compound is deemed to possess a mitochondrial liability if
EC50-ATP glucose/EC50-ATP galactose ≥ 2. There were no
significant differences in ATP levels between glucose or
galactose media for all treatment regimens, indicating that
flucloxacillin does not cause mitochondrial toxicity mediated
via electron transport chain dysfunction (Figure S2).
To assess whether covalent binding of flucloxacillin to
proteins in the liver cells is responsible for the observed tissue
injury, the hepatocyte cell lines HepG2 and HepaRG were
treated with flucloxacillin (0.5−1.5 mM) for 24 h. Cell lysates
were separated by SDS-PAGE and probed with anti-
flucloxacillin antibodies that are highly specific to flucloxacillin
(Figure S3) to detect intracellular protein adduct formation.
Coomassie blue SDS-PAGE shows no alteration in protein
abundance across flucloxacillin treatments in lysates extracted
from HepG2 and HepaRG cell lines (Figure 1A). Western blot
analysis using anti-flucloxacillin antibody reveals covalent
binding after 24 h of treatment in both cell lines in a dose-
dependent manner (Figure 1B). It is important to note that
flucloxacillin forms protein adducts in HepaRG cells at lower
concentrations compared with HepG2 cells, indicating cellular
disposition of flucloxacillin is different between these two cell
types. It has been shown that the efflux transporter, multidrug
resistance-associated protein 2 (MRP2), is expressed equiv-
alently in HepaRG and primary hepatocytes, however, it is not
expressed in HepG2 monolayer cell cultures. Another efflux
transporter, P-glycoprotein (P-gp), was found to be expressed
equivalently in HepG2 cells, while overexpressed in HepaRG
cells.9 The different expression levels of efflux transporters may
contribute to the cellular flucloxacillin concentration and
consequently the levels of protein adduct. Immunocytochem-
istry further confirmed that covalent binding in HepaRG cells
was dose dependent (Figure 1C).
We next employed immunocytochemistry to determine the
localization of flucloxacillin-modified proteins using HepaRG
cells. HepaRG cells were selected for this study due to their
ability to terminally differentiate into hepatocellular epithelial-
like cells and form bile canaliculi (BC). The expression of the
efflux membrane transporters MRP2 and P-gp on HepaRG
cells was detected using anti-MRP2 and anti-P-gp antibodies.
These transporters were localized within the tight actin
bundles (Figure S4A). The activity of MRP2 and P-gp was
assessed using CMFDA, a membrane-impermeant fluorescent
dye. Inhibition of MRP2 and P-gp (using MK571 and
valspodar, respectively) resulted in a reduced CMFDA
accumulation within the HepaRG BC (Figure S4B). Upon
incubation of HepaRG cells with 1.5 mM flucloxacillin,
immunofluorescence imaging revealed a localization of protein
adducts within the BC, mirroring the localization of MRP2 and
P-gp. These data indicate the active transport of flucloxacillin
from hepatocytes into the bile epithelia (Figure 2A). We then
examined the effect of drug treatment on BC morphology
using an anti-MRP2 antibody. Immunofluorescence imaging
showed that exposure to flucloxacillin (1.5 mM) led to BC
dilatation in a time-dependent manner. Initial BC dilation was
visualized upon 24 h treatment, with further dilation occurring
after 7 days (Figure 2B).
To further examine the effect of transporters on the covalent
binding of flucloxacillin to hepatocellular proteins, MK571 and
valspodar were used to block the activity of MRP2 and P-gp,
respectively. Cells were cultured in the presence of 1.5 mM
flucloxacillin overnight with the addition of one or both of the
transporter blockers. Prior to incubation with flucloxacillin,
cells were pretreated with their respective blockers for 1 h. In
the control (no membrane transporter inhibitors), fluclox-
acillin can easily be seen localizing within the BC (Figure
S5A). Upon the addition of the MRP2 block, the levels of
flucloxacillin adducts localized within BC reduced. Instead,
covalent binding of flucloxacillin contained within the
cytoplasm appeared to be increased (Figure S5B). Interest-
Figure 1. Flucloxacillin forms protein adducts in human hepatocyte-like cells. (A) Coomassie blue SDS-PAGE shows no alteration in protein
abundance across flucloxacillin treatments in lysates extracted from HepG2 and HepaRG cell lines. (B) Western blot analysis using antiflucloxacillin
antibody reveals covalent protein binding after 24 h of treatment in both cell lines in a dose-dependent manner. Proteins extracted from HepaRG
cells are modified by flucloxacillin at lower concentrations compared with HepG2 cells. (C) Covalent binding in HepaRG cells is observed at 0.5
and 1.5 mM concentrations in a dose-dependent manner. Red = F-actin, blue = nuclear staining, and green = flucloxacillin.
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ingly, inhibition of P-gp had no observable effects on
flucloxacillin adducts formation in BC (Figure S5C). As
expected, the levels of intracellular flucloxacillin modification
were increased when both MRP2 and P-gp were inhibited
(Figure S5D,E).
The flucloxacillin protein adducts located at the BC, the
primary site of tissue injury in patients with cholestasis, could
potentially activate both immune and non-immune pathways
involved in liver injury. We have recently shown that
flucloxacillin protein adducts formed in immune cells can be
processed and presented by HLA-B*57:01.7 It is plausible that
the protein adducts within BC can be presented by the local
antigen presenting cells, e.g. cholangiocytes, leading to
activation of residential immune cells.10 In addition, we have
demonstrated that hepatocyte-derived exosomes transport
flucloxacillin-modified liver proteins to dendritic cells. Peptides
derived from the flucloxacillin-modified liver proteins activated
naiv̈e T-cells from healthy human donors.11 Therefore,
flucloxacillin hepatocyte-derived antigenic signals can activate
immune cells through either direct or indirect presentation. On
the other hand, covalent binding of flucloxacillin to proteins
within BC may induce local hepatic stress. As a molecular
initiating event, the hepatic stress may promote pathological
inflammatory responses via multiple pathways. Flucloxacillin
has recently been shown to induce direct cholestatic injury in
in vitro cultured human HepaRG cells through PKC/P38 and
PI3K/AKT signaling pathways. At high concentrations (>6
mM), cholestatic injury was evidenced by dilation of BC,
reduced bile acid efflux, and secretion of hepatocyte pro-
inflammatory cytokines such as IL-6 and IL-1β.1,2,12 The
alteration of BC morphology by flucloxacillin was further
confirmed by the current study when a lower concentration of
drug was used (1.5 mM). Flucloxacillin treatment of primary
human hepatocytes was also associated with the release of
high-mobility group box 1 protein and dendritic cells exposed
to flucloxacillin-treated hepatocyte supernatant secreted TNF-
α, IL-6, and IL-1β.11 Thus, signaling pathways between
flucloxacillin-treated hepatocytes and immune cells could
potentiate drug- and tissue-specific adaptive immune attack.
Collectively, these data suggest that covalent binding of
flucloxacillin to local proteins at the site of tissue injury may
activate both immune and non-immune-mediated pathways,
leading to liver injury. It is important to note that the levels of
covalent binding and the dilation of BC are concentration and
time dependent, indicating accumulation of protein adducts at
the site of tissue injury could be an important risk factor.
Although flucloxacillin-induced liver injury is idiosyncratic and
associated with multiple risk factors, the risk of injury was
Figure 2. Localization of flucloxacillin protein adducts. (A) Flucloxacillin (1.5 mM) treatment (green) for 16 h resulted in the localization of drug
within the bile canaliculi, as observed in the maximum intensity projection (i) and Z-stack images (ii) (white arrows). (B) Anti-MRP2 antibody
(green) was used to detect the expression of MRP2 in HepaRG cells to identify biliary cells. Bile canaliculi were shown to become dilated after
prolonged flucloxacillin exposure. Red = F-actin and blue = nuclear staining.
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indeed increased with the increasing number of prescriptions
and prolonged duration of use.13 Further studies are warranted
to establish the quantitative relationship between the covalent
binding and toxicological outcome. Further investigation of
whether flucloxacillin is a substrate or inhibitor of MRP2 and
P-gp will help define the roles of these transporters in
flucloxacillin-induced cholestatic liver injury.
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